Drug Trial Radar · NCT02503306
Efficacy and Tolerability Study of Avanafil in Russia
Last checked: Nov 20, 2026Latest source record: Mar 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
189
Actual
Start
Jul 2015
Primary completion
Mar 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: o To assess the change in percent of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse between the run-in period and treatment period: * The change in percent of sexual attempts in which subjects are able to insert the penis into the partner's vagina. * The change in score on the erectile function (EF) domain of the International Index of Erectile Function (IIEF) questionnaire. Secondary Objective: o To evaluate the safety and tolerability of avanafil in patients with erectile dysfunction (ED).
Conditions
- Sexual Function and Fertility Disorders NEC-Erectile Dysfunction
Interventions
AVANAFILDrug
Pharmaceutical form:tablets Route of administration: oral
placeboDrug
Pharmaceutical form:tablets Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the percentage of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourseTime frame: 12 weeks
- Change in the percentage of sexual attempts in which subjects are able to insert the penis into the partner's vaginaTime frame: 8 weeks
- Change from baseline in EF scoreTime frame: baseline and 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.